Is Extracorporeal Shock Wave Therapy Effective in the Treatment of Myofascial Pain Syndrome?

Jong-Ick Kim, Hyo-Jin Lee, Hyung-Youl Park, Won-Hee Lee, Yang-Soo Kim

Department of Orthopedic Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Department of Orthopedic Surgery, Barunsesang Hospital, Seongnam, Korea

Background: Extracorporeal shock wave therapy (ESWT) is one of the treatment options used for patients with myofascial pain syndrome (MPS), although its effectiveness is controversial. The purpose of this study was to evaluate the effectiveness of ESWT in the treatment of MPS in terms of pain relief and functional improvements.

Methods: We assessed 93 patients with MPS who underwent ESWT from March 2009 to July 2014. After exclusion of 25 patients with shoulder diseases, 68 patients were enrolled in the study. The mean follow-up period was 7.5 months (± 4.2 weeks), and the average duration of symptoms was 5 months (range, 2–16 months). ESWT was applied to intramuscular taut bands and referred pain areas once a week for 3 weeks. Visual analog scale (VAS) pain scores and American Shoulder and Elbow Surgeons (ASES) scores were obtained at an initial assessment and at the 6-week, 3-month, and 6-month follow-up assessments.

Results: VAS pain scores and ASES scores improved significantly after 3 sessions of ESWT (p < 0.05). Both scores were improved, although not significantly, after 6 weeks (p > 0.05).

Conclusions: ESWT is an effective treatment option for patients with MPS.

Key Words: Myofascial pain syndromes; Extracorporeal shock wave lithotripsy; Visual analog scale

Introduction

Myofascial pain syndrome (MPS) is a painful condition arising from skeletal muscle trigger points. Application of manual pressure to these trigger points can induce local and referred pain consistent with the patient’s symptoms. The diagnosis of MPS is based on several clinical manifestations, including tender points around the levator scapulae, trapezius, and infraspinatus muscle belly, referred pain to the occipital area and periscapular area, and palpable intramuscular taut bands. The treatment options for MPS include pharmacological and non-pharmacological interventions. Nonsteroidal anti-inflammatory drugs (COX-II inhibitors) and muscle-relaxant agents (afloqualone, GABAergic drugs) are commonly used for treatment of MPS. Because an intramuscular taut band remaining after pharmacological treatment may produce continuous pain, dry needling is occasionally performed to eliminate the band. However, dry needling is an invasive technique. Less invasive treatments such as extracorporeal shock wave therapy (ESWT) have recently introduced. Effectiveness of ESWT has been demonstrated in treatment of lateral epicondylitis, calcific tendinitis, planter fasciitis, and tendinitis surrounding various joints.

The purpose of this study was to evaluate the effectiveness of ESWT in the treatment of MPS in terms of pain relief and functional improvements.

Methods

Ninety-three patients diagnosed with MPS in Seoul St. Mary’s Hospital from March 2009 to July 2014 were reviewed. Shoul-
Is ESWT Effective in the Treatment of Myofascial Pain Syndrome?
Jong-Ick Kim, et al.

Assessed for eligibility (n=93)

Excluded (n=25)
Stiffness (n=10)
Rotator cuff tear (n=10)
Calcific tendinitis (n=5)

68 patients enrolled

68 patients followed-up at 6 weeks

52 patients followed-up at 3 months

Lost to follow-up (n=16)

35 patients followed-up at 6 months

Lost to follow-up (n=17)

Fig. 1. Flowchart showing the study protocol according to Consolidated Standards of Reporting Trials criteria.

Table 1. VAS Pain Scores and ADL Scores and ASES Scores Improved after 3 Sessions of ESWT

<table>
<thead>
<tr>
<th>Variable</th>
<th>Initial</th>
<th>6 weeks</th>
<th>3 months</th>
<th>6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
<td>p-value</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>VAS</td>
<td>4.82 ± 1.17</td>
<td>3.28 ± 0.72</td>
<td>&lt;0.001</td>
<td>3.17 ± 0.92</td>
</tr>
<tr>
<td>ADL</td>
<td>22.80 ± 2.69</td>
<td>26.40 ± 1.83</td>
<td>&lt;0.001</td>
<td>26.20 ± 2.08</td>
</tr>
<tr>
<td>ASES</td>
<td>63.85 ± 8.75</td>
<td>77.57 ± 6.38</td>
<td>&lt;0.001</td>
<td>77.80 ± 7.32</td>
</tr>
</tbody>
</table>

Comparison with scores at initial visit and the other visits showed statistically significant difference (p<0.05).


Some patients had previously undergone several treatments (e.g., physical therapy, manual massage, medication, or dry needling); however, none had received treatment within 3 months prior to presenting to our hospital, and none of the patients had previously undergone ESWT. Patients had other associated diseases, such as cervical spine spondylosis. All patients underwent 3 sessions of ESWT during a 3-week period. Follow-up assessments were performed at 3 months for 52 patients (76.5%) and at 6 months for 35 patients (51.5%) (Fig. 1).

The above-mentioned pharmacological agents were administered to all patients in conjunction with ESWT treatment. Both nonsteroidal anti-inflammatory drugs and muscle relaxants were used, but the type and dosage varied according to the degree of patient compliance. ESWT was administered as 4,000 impulses of 0.25 mJ/mm$^2$ at a frequency of 7 Hz using the Swiss DolorClast (Electro Medical Systems, Nyon, Switzerland). Pressure was set at 3 bar, and a radial type shock wave was used. After receiving a diagnosis of MPS, all patients underwent ESWT once a week for 3 weeks (for a total of 12,000 impulses). One member of our shoulder team applied ESWT to the intramuscular taut band and referred pain area, which mainly included the trapezius or levator scapula muscles (1–2 tender points). An additional session or two was performed in patients who wanted more than 3 ESWT treatments.

A 10-point visual analog scale (VAS) for pain intensity (where 0=no pain and 10=worst possible pain) was used to measure each patient’s response to ESWT. VAS pain scores and American Shoulder and Elbow Surgeons (ASES) scores were checked at the initial visit and at the 6-week, 3-month, and 6-month follow-up visits. These scores are widely used at orthopedic clinics for evaluation of subjective clinical outcomes.

Statistical analyses were performed using SPSS software ver. 12.0 (SPSS Inc., Chicago, IL, USA). The paired t-test was used for comparison of differences in the functional evaluation scores before and after treatment. A p-value <0.05 was considered significant.

Results

Six weeks after ESWT treatment, VAS pain scores had improved in 47 patients, deteriorated in 8 patients, and were similar in 13 patients. Three months after ESWT treatment, pain scores had improved in 30 patients, deteriorated in 12 patients, and were similar in 10 patients. Six months after ESWT treatment, pain scores had improved in 16 patients, deteriorated in 10 patients, and were similar in 9 patients.
A significant improvement in VAS pain scores was observed after 3 sessions of ESWT ($p<0.05$) (Table 1). Six weeks after ESWT, the mean VAS pain score had improved from 4.82 points to 3.28 points. At 3 and 6 months, the mean pain score had improved from 4.82 points to 3.17 points and from 4.82 points to 3.02 points, respectively. No significant differences were found between scores measured at 6 weeks and 3 months, 6 weeks and 6 months, and 3 months and 6 months. After 6 weeks follow-up assessment, the mean VAS score had improved, but not significantly ($p>0.05$) (Fig. 2).

Activities of daily life (ADL) scores also improved significantly after 3 sessions of ESWT ($p<0.05$) (Table 1). Six weeks after treatment, the mean ADL score had improved from 22.80 points to 26.40. At 3 and 6 months, mean ADL scores had improved from 22.80 points to 26.20 points and from 22.80 points to 26.25 points, respectively. No significant differences were found between scores measured at 6 weeks and 3 months, 6 weeks and 6 months, and 3 months and 6 months. After 6 weeks follow-up assessment, the mean ADL score had improved, but not significantly ($p>0.05$) (Fig. 3).

ASES scores also showed significant improvement after 3 sessions of ESWT ($p<0.05$) (Table 1). Six weeks after treatment, the mean ASES score had improved from 63.85 points to 77.57. At 3 and 6 months, mean ASES scores had improved from 63.85 points to 77.80 points and from 63.85 points to 78.61 points, respectively. No significant differences were found between scores measured at 6 weeks and 3 months, 6 weeks and 6 months, 3 months and 6 months. After 6 weeks follow-up assessment, the ASES score had improved, but not significantly ($p>0.05$) (Fig. 4).

VAS pain scores and ADL scores both improved after 3 sessions of ESWT. We conclude that both improvements contributed to the improvements in the ASES score.

**Discussion**

The mechanisms of ESWT are unclear, however several hypotheses have been proposed based on the cellular and molecular effects of this treatment.\textsuperscript{10,13} ESWT improves blood circulation in capillaries, and it reduces the tension and stiffness of muscles, which can interfere with blood flow and cause excessive stimulation of nociceptors and nerves.\textsuperscript{14} According to De Sanctis et al.,\textsuperscript{15} ESWT improves capillary blood circulation in chronic ischemic zones. Referred pain in patients with MPS is due to the ease of inducing central sensitization, because the peripheral muscle nociceptor threshold is lower than that in other systems.\textsuperscript{16} ESWT may interrupt the cascade of referred pain by
inhibiting peripheral muscle nociceptors and reducing levels of substance P. According to Hausdorf et al., ESWT reduces musculoskeletal tissue pain by selectively destroying non-myelinated fibers, and it reduced substance P levels in the dorsal root ganglia in an animal study.

The prevalence of MPS is 21% to 85% among individuals with regional pain. Despite its high prevalence rate, the pathophysiology of MPS remains unclear. Travell and Simons proposed that damaged muscle fibers become shortened by calcium reflux into the fibers or by acetylcholine secretion at the motor endplate. Ji et al. hypothesized that MPS originates from an abnormal increase in the production and release of acetylcholine, which induces sustained depolarization of the post-junctional muscle fiber membrane. Released acetylcholine may cause a continuous release and uptake of calcium ions and produce muscle ischemia as a result of sustained sarcomere shortening and the release of sensitizing substances, such as substance P, bradykinin, calcitonin gene-related peptide, tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and IL-8. ESWT may reduce the pain associated with MPS by promoting angiogenesis and increasing perfusion in ischemic tissues and by altering pain signaling at the ischemic tissues caused by calcium influx.

Multiple factors can cause muscle pain around the shoulder and neck. MPS can be caused by poor posture, emotional stress, obsessive-compulsive disorders, or cervical spine disc disease, and these problems influence one another. Therefore, treating only one of these causes cannot guarantee good results, and achievement of complete remission can be difficult for patients with MPS. ESWT softens taut muscular bands, however other factors such as poor posture or emotional stress cause symptom recurrence. The rapport between the doctor and patient is important so that treatment can be continued and patients can be advised about recurrence. A sufficient treatment period and good patient compliance are also important.

In this study, we investigated the effects of ESWT in the treatment of MPS of the shoulder by evaluating clinical scores. Few studies have reported a correlation between MPS and shoulder scores. In this study, ESWT was applied once a week for 3 weeks. After the treatment period, clinical and pain scores showed significant improvements. Symptoms and scores were slightly better at 3 months and 6 months after treatment than at 6 weeks, although this difference was not statistically significant. It is currently unknown how many sessions of ESWT are required for treatment of MPS, and more studies are required to establish these guidelines.

The limitations of this study include the small patient group, the short-term follow-up period, and the absence of a control group. An additional case-control study using other treatment options will be necessary, as this was the weakest point of our study. Because no diagnostic tools have been confirmed for MPS, our diagnosis mainly depends on the physical examination. Another limitation of this study is that our patient group was heterogeneous in nature, but these differences were not addressed.

Conclusion

VAS pain scores and ASES scores improved after ESWT treatment. ESWT currently represents one of the most effective treatment options for patients with MPS.

References


www.cisejournal.org 23